Over a third of UK listed biotech firms collapsed after the 2008 financial crisis.

Evidence

More than a third—twenty-nine companies—of the [UK] listed biotech sector have gone bust since 2008 and ten are on the brink, according to work by Paul Cuddon at analysts Peel Hunt. Another thirty-eight are ”fine” and six were bought by other companies. — Kean Birch, Rethinking Value in the Bio-economy, 7

Categorization

• QUESTION: Which companies survived and why? A survival analysis of the UK biotech bust would test the article’s assetization thesis against which firms kept their financing.
• XREF: Connects to the financialization of science literature and to the dot-com bubble’s biotech equivalents — plausibly resonates with a finance-library reader’s work on distressed R&D-heavy sectors.
• CANDY: A crisp, quoteable stat: most of a whole national biotech sector went bust after 2008.